



**Solid Research
Solid Relationships**

Fundamental Outlook

Market Setup

- **US Markets** on Monday **ended upto -0.5% lower**, as investors looked for moves toward Middle East de-escalation and waited for earnings reports due from major technology companies later in the week.
- **Dow Futures** is currently **60 points up (+0.1%)**.
- **Asian markets** are mostly trading **1-2% higher**.
- **Domestic equity markets** remained under pressure, with the **Nifty 50 declining 0.4%**, while broader markets outperformed as the **Nifty Midcap 100** and **Nifty Smallcap 100 gained 0.6%/0.2%**, respectively.
- **Gift nifty** is currently trading **with the loss of 0.6% (-133 pts)**
- **FII's: -1,121Cr; DII's: 1,312Cr**

Opening Cues: **Negative**

Interglobe Aviation: IndiGo has signed a MoU with CFM International for an order of more than 1,000 LEAP-1A engines to power 510 Airbus A320neo Family aircraft. This will be the largest single order ever placed for LEAP engines and a record for CFM International. The MoU also includes CFM's extensive support in establishing IndiGo's upcoming engine maintenance, repair, and overhaul (MRO) facility, as well as supporting IndiGo's rapidly growing fleet through a long-term material service

View: **Positive**

TCS: As per media reports, TCS has acquired two land parcels in Vizag and Pune for Rs640 crores, which could house US-headquartered OpenAI's first data facilities in India.

View: **Positive**

IPO Listing Today: SBI Funds Management

Results Declared:

Beat: Paytm, JK Cement, Canara HSBC Life Insurance, Mahindra Logistics

Inline: Ultratech, Oberoi Realty, Can Fin Homes

Fundamental Actionable Idea

Emcure Pharma

CMP: INR 1,862, TP: INR 2,260, 21% Upside, Buy, MTF Stock

- Emcure Pharma is an R&D-driven diversified pharmaceutical company with a balanced domestic and international presence.
- EMCURE has built a diversified chronic-focused domestic franchise led by women's health and expanded into cardiology, central nervous system, anti-diabetes, HIV and oncology through strong brand building, field-force expansion and strategic partnerships with Sanofi, Novo Nordisk and Roche.
- Internationally, acquisitions such as Marcan, Mantra and Manx, along with a pipeline of complex injectables, biologics and specialty products, are expected to sustain growth across regulated markets.
- Yesterday it also announced that its co-marketed brand, Poviztra, has secured approval from the Central Drugs Standard Control Organisation (CDSCO) for treating non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis (F2-F3).
- Backed by strong growth across regulated international markets and a diversified domestic franchise, Emcure is expected to deliver a CAGR of 14%/20%/28% in revenue/EBITDA/PAT over FY26–28, supported by differentiated product launches, operating leverage and an average RoE of around 20%.

View: BUY

Fundamental Actionable Idea

Paytm

CMP: INR1,348; MTF Stock

- PayTm reported a strong growth of 8% QoQ (up 28% YoY) in Revenue to INR24.5b (inline). GMV growth was robust (up 31% YoY/ 9% QoQ) to INR7.1t (4% beat), aided by market share gains in offline business and tailwinds in online business, post receipt of online PA license last year.
- Net Payment Margin grew 13% YoY/ 3% QoQ to INR6b, declined to 8bp of GMV vs 9bp in 4QFY26 and 10bp in 3QFY26, amid faster growth in payments processing charges.
- Contribution profit stood thus healthy by 17% YoY/ 8% QoQ to INR13.5b (inline). Contribution margin stood steady at 55.1% vs 55.4% in 4QFY26 (inline to MOSLe of 55.5%). EBITDA thus increased by 183% YoY/ 54% QoQ to INR2.03b (MOSLe of INR1.8b). EBITDA margin improves to 8.3% vs 5.8% in 4QFY26. Company reported net profit of INR2.2b (vs our est of INR2.0b).
- Paytm decides to defer proposal to issue bonus shares. On the other hand, plans for an investment of up to Rs 100 crore in its subsidiary Paytm Money Limited via rights issue

View: Positive

Result Estimate – 21st July, 2026

Q1FY27 Expectations	Revenue (₹ Cr.)	Growth (%)		EBIDTA (₹ Cr.)	Growth (%)		PAT (₹ Cr.)	Growth (%)	
Company	Jun-26	YoY	QoQ	Jun-26	YoY	QoQ	Jun-26	YoY	QoQ
Bajaj Auto	16,858	34%	5%	3,398	37%	2%	2,755	31%	1%
Cyient DLM	351	26%	-5%	34	35%	-22%	16	119%	-27%
M & M Financial	2,431	21%	2%	1,721	27%	0%	749	41%	-14%
Granules India	1,441	19%	-2%	329	33%	-7%	177	33%	-6%
Gabriel India	1,465	33%	21%	108	3%	-4%	101	63%	51%
TVS Motor	13,450	33%	5%	1,641	30%	-2%	1,013	30%	2%
Atlanta Electricals	410	30%	-45%	68	39%	-55%	35	12%	-66%
Bandhan Bank	2,895	5%	4%	1,345	-19%	-7%	461	24%	-14%
AAVAS Financiers	325	17%	2%	230	21%	-3%	171	23%	-6%
Aditya Birla AMC	460	3%	0%	261	-2%	-2%	256	-7%	37%
Sagility	1,886	23%	-7%	422	22%	-13%	225	13%	-27%
JSW Infra	1,405	15%	-8%	645	11%	-16%	375	5%	-26%
Sunteck Realty	226	20%	-33%	61	28%	-37%	33	0%	-47%
Arvind Fashions	1,258	#VALUE!	-8%	156	#VALUE!	-18%	2	-81%	-94%
Trident	1,826	7%	12%	246	-15%	1%	122	-11%	5%
Indiamart Inter.	408	10%	1%	135	1%	2%	118	-23%	136%
Indian Hotels	2,311	13%	-16%	657	14%	-32%	357	20%	-41%

Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Velocity Idea

Velocity Idea – Max Healthcare

RECO: BUY; CMP: ₹1,132; SL: ₹1035(8.6%); TGT: ₹1329(17%)

- Noida's underpenetrated market creates structural demand. The region—with 1.3m population growing 5.4% CAGR—has just ~4.5K super specialty beds, creating significant structural tailwinds for capacity expansion. Max is adding ~4K beds over 4yrs across brownfield (Smart, Nanavati, Mohali) & greenfield projects (Gurgaon). Phased approach reduces execution risk & provides growth visibility through FY28.
- Recent Jaypee acquisition(Noida) validates Max's operational excellence and replicable playbook. Within just one year of acquiring the 407-bed facility, Max increased occupancy from 64% to 72%, boosted ARPOB from ₹57k to ₹67k, and grew monthly revenue from ₹360m to ₹570m through specialized services and doctor retention.
- Overall, we expect a CAGR of 13%/17%/21% in revenue/EBITDA/PAT over FY26-28., supported by capacity additions and operating leverage.
- The Stock has broken out from a falling supply trendline with a strong bodied bullish candle on the daily chart.
- The ADX line is rising which confirms the strength of the bullish trend.

Diversified Lending Basket

- NBFCs are entering FY27 from a position of strength, with cleaner balance sheets and improving asset quality after nearly two-and-a-half years of risk recalibration. The easing of the US–Iran conflict and correction in crude prices have reduced macro risks, supporting borrower cash flows and creating a favorable environment for credit growth.
- Improving banking system liquidity and a stable interest rate environment are expected to lower incremental borrowing costs and enhance funding availability for NBFCs. This should support faster loan growth, better margins, and improved profitability across well-capitalized lenders.
- The combination of healthier balance sheets, easing funding costs, and resilient credit demand positions NBFCs for the next earnings upcycle. Diversified retail-focused lenders with disciplined underwriting are well placed to benefit from improving growth, margins, and asset quality.

Time Frame: 12 months

Review: Monthly

Upside: 15–20%

Risk: High

Benchmark: Nifty 200

Script	Market Cap (in Cr.)	CMP as on 13 th July 2026	Weightage (%)
Shriram Finance	2,45,800	1,049	20
L&T Finance	81,900	325	20
Manappuram Finance	31,300	331	20
CreditAccess Grameen	24,300	1,538	20
Five Star Business Finance	16,100	542	20

Weightage Rationale: We have assigned equal weightage to all the stocks in the basket as we expect equal growth opportunity in each of them.

*Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Focus Investment Ideas

All Stocks Available in MTF

Duration : 1 Year Horizon

Stock Name	Rating	CMP (Rs)	Target (Rs)	Upside (%)
State Bank of India	Buy	1,060	1,300	23%
Lenskart	Buy	540	655	21%
Shriram Finance	Buy	1,036	1,230	19%
Cummins India	Buy	5,525	6,600	20%
Titan	Buy	4,639	5,250	13%

Technical Outlook

Nifty Technical Outlook

21-Jul-26

NIFTY (CMP : 24238) Nifty immediate support is at 24100 then 24000 zone while resistance at 24400 then 24500 zones. Now it has to cross and hold above 24250 for an up move towards 24400 then 24500 zones while support can be seen at 24100 and 24000 zones.

4-Nifty50 - 20/07/26
EMA(CloseLine:20)



Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Sensex Technical Outlook

21-Jul-26

Sensex (CMP : 77708) Sensex support is at 77300 then 77000 zones while resistance at 78200 then 78500 zones. Now it has to cross and hold 77800 zones, for a bounce towards 78200 then 78500 marks while on the downside support are seen at 77300 and then 77000 zones.



Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Bank Nifty Technical Outlook

21-Jul-26

BANK NIFTY (CMP : 57945) Bank Nifty support is at 57750 then 57500 zones while resistance at 58500 then 58750 zones. Now it has to cross and hold above 58000 zones for a bounce towards 58500 then 58750 levels while on the downside support is seen at 57750 then 57500 zones.

4-Niftybank - 20/07/26
EMA(CloseLine:20)



Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Midcap100 Index Technical Outlook

- Index is on the verge of breakout above 63185 marks.

21-Jul-26



Nifty Midcap100 Stats

Advance	Decline
70	30

Smallcap250 Index Technical Outlook

- Index is consolidating in a range and hovering near 20 DEMA.



Nifty SmallCap250 Stats

Advance	Decline
126	124

Sectoral Performance - Daily

Almost all the sectors ended on flattish note.


	Closing	% Change				
Indices	20-Jul	1-day	2-days	3-days	5-days	
NIFTY 50	24239	-0.39%	0.69%	0.66%	0.11%	
NIFTY BANK	57945	-0.98%	0.63%	0.32%	-0.32%	
NIFTY MIDCAP 100	62802	0.60%	0.18%	-0.22%	-0.38%	
NIFTY SMALLCAP 250	18024	0.11%	-0.47%	-0.41%	-0.81%	
NIFTY FINANCIAL SERVICES	26575	-1.22%	0.07%	-0.44%	-0.97%	
NIFTY PRIVATE BANK	27862	-2.27%	-0.19%	-0.50%	-1.04%	
NIFTY PSU BANK	8615	2.78%	3.20%	2.72%	1.83%	
NIFTY IT	29162	-0.22%	1.53%	2.21%	0.50%	
NIFTY FMCG	49067	0.65%	1.36%	1.62%	0.53%	
NIFTY OIL & GAS	11369	0.62%	1.62%	1.70%	1.72%	
NIFTY PHARMA	26003	1.40%	-0.02%	0.00%	1.40%	
NIFTY AUTO	27028	-0.26%	0.97%	1.44%	0.17%	
NIFTY METAL	12544	0.86%	0.38%	0.05%	-0.46%	
NIFTY REALTY	918	-0.13%	1.25%	0.26%	-2.10%	
NIFTY INDIA DEFENCE	9364	0.20%	0.84%	0.35%	-0.53%	



Sectoral Performance - Weekly

- Some positive momentum is seen in Nifty Realty

21-Jul-26



Name	1W Change	2W Change	3W Change	4W Change	5W Change
Nifty 50	-0.39	0.13	-0.13	0.76	0.94
Nifty Bank	-0.98	-0.17	0.01	-0.4	0.45
Nifty IT	-0.22	4.11	6.28	6.7	6.33
Nifty Auto	-0.26	0.62	0.15	0.19	1.67
Nifty Metal	0.86	-1.14	-0.43	0.79	-3.66
Nifty Pharma	1.4	1.28	1	4.14	6.31
Nifty FMCG	0.65	-0.49	-2.05	-0.71	-0.99
Nifty Realty	-0.13	-2.25	3	11.04	13.01
Nifty Media	1.09	3.62	1.7	1.87	1.49
Nifty PSU Bank	2.78	1.93	2.47	-0.24	-1.16

LLOYD METALS

(Mcap ₹ 1,07,397 Cr.)

MTF stock

- Stock has retested trend line breakout and inched higher .
- Stock has formed bullish candle.
- Surge in volumes visible.
- We recommend to buy the stock at CMP ₹1908 with a SL of ₹ 1800 and a TGT of ₹ 2070.

RECOs	CMP	SL	TARGET	DURATION
BUY	1908	1800	2070	1 Week



Technical Stocks On Radar

UNION BANK OF INDIA

(CMP: 176, Mcap ₹ 1,34,298 Cr.)

F&O Stock, MTF stock

- Stock is on the verge of breakout above 177.50.
- Noticeable volumes.
- RSI is trending upward.
- Immediate support at 171



NAVIN FLUORINE

(CMP: 7862, Mcap ₹ 40,328 Cr.)

MTF stock

- Stock has given trend line breakout.
- Formed a strong bullish candle.
- RSI has given positive crossover.
- Immediate support at 7600.



Derivative Outlook

Nifty : Option Data

- Maximum Call OI is at 24300 then 24500 strike while Maximum Put OI is at 24200 then 24100 strike.
- Call writing is seen at 24250 then 24300 strike while Put writing is seen at 24200 then 24150 strike.
- Option data suggests a broader trading range in between 23700 to 24700 zones while an immediate range between 24000 to 24500 levels.



Option - Buying side strategy

Index	Single Leg Buying	Multi Leg Strategy
Nifty (Weekly)	24200 Call if it cross and holds above 24250 zones	Bull Call Spread (Buy 24200 CE and Sell 24300 CE) at net premium cost of 45-50 points
Sensex (Weekly)	78100 Call if it cross and holds above 77800 zones	Bull Call Spread (Buy 78200 CE and Sell 78400 CE) at net premium cost of 60-70 points
Bank Nifty (Monthly)	58800 Call if cross and holds above 58000 zones	Bull Call Spread (Buy 58000 CE and Sell 58500 CE) at net premium cost of 230-240 points


Option - Selling side strategy

Index	Writing
Nifty (Weekly)	24000 PE and 24400 CE
Sensex (Weekly)	75400 PE and 79200 CE
Bank Nifty (Monthly)	56000 PE and 59600 CE


Weekly Option Range for Option Writers based on Different Confidence Band								
Date		21-Jul-26	Weekly Expiry		21-Jul-26	Days to weekly expiry		1
								
Nifty		24239	India VIX		13.0			
Confidence Band	Probability	% Away From Spot	Range				Total Premium (Put + Call)	Types of Trades
			Put	Premium	Call	Premium		
1.00	68%	± 0.6%	24100	22	24400	18	40	Aggressive
1.25	79%	± 0.8%	24050	16	24450	10	26	Less Aggressive
1.75	92%	± 1.0%	24000	11	24500	6	17	Conservative
2.00	95%	± 1.2%	23950	8	24550	3	11	Most Conservative
Date		21-Jul-26	Monthly Expiry		28-Jul-26	Days to weekly expiry		6
Bank Nifty		57945						
Confidence Band	Probability	% Away From Spot	Range				Total Premium (Put + Call)	Types of Trades
			Put	Premium	Call	Premium		
1.00	68%	± 1.8%	56900	142	58900	198	340	Aggressive
1.25	79%	± 2.3%	56600	101	59200	123	224	Less Aggressive
1.50	87%	± 2.8%	56300	74	59500	78	152	Neutral
1.75	92%	± 3.2%	56100	60	59700	56	116	Conservative
2.00	95%	± 3.7%	55800	45	60000	36	81	Most Conservative
Investments in securities markets are subject to market risks. Please read all related documents carefully.								

Nifty Advance Decline & Ban update

Stocks in Ban: KAYNES



Stocks : Derivatives Outlook



Stocks : Options on radar

Stock	Call Strike	Trade	Buying Range	SL	TGT	Logic
TORNTPHARM	5000 CE	Buy	55-60	40	90	Long Buildup
SOLARINDS	19250 CE	Buy	350-360	310	450	Long Buildup
MANKIND	2580 CE	Buy	47-50	40	65	Short Covering

Stock	Call Strike	Trade	Buying Range	SL	TGT	Logic
AXISBANK	1260 PE	Buy	18-20	15	30	Short Buildup
MARUTI	13500 PE	Buy	200-210	160	300	Long Liquidation

Siddhartha Khemka
Head – Retail Research

Chandan Taparia, CMT, CFTE, MFTA
Head – Derivatives & Technical Research

Ruchit Jain
Head – Technical Research

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report..

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Analyst ownership of the stock	No
--------------------------------	----

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) “SFO”. As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to “Professional Investors” as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors.” Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. (“MOCMSPL”) (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as “institutional investors” as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore (“SFA”) or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an “institutional investor” nor an “accredited investor”, they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Disclaimer:

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be` suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.